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A new method for the study of carbohydrate chain biosynthesis of amphipathic glycosphingolipids is 
presented. The method takes advantage of the thin-layer plate which is used as a solid matrix for precursor 
glycosphingolipids in biosynthetic experiments after chromatographic development of the precursor 
sample. The method is shown to be simple, fast and sensitive. It,minimizes ‘the risk-of adding unwanted 
exogenous precursors and abolishes the need for tedious purification of products after incubation. The 
method opens up new possibilities for the biosynthetic study of mixtures of glycosphingolipids. 
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1. INTRODUCTION 
Glycosyltransferases taking part in glycoprotein 
biosynthesis have been detected, purified and 
characterized from a number of sources, but very 
little work has been published on the biosynthesis 
in vitro of blood group glycosphingolipids [1,2]. 
Most biosynthetic experiments with glycosphin- 
golipid precursors have been carried out by study- 
ing the transfer of a radioactive sugar unit from a 
sugar nucleotide donor to a glycolipid acceptor in 
the presence of, for example, an enzyme (purified 
or non-purified), detergents or buffer [2]. The 
limited availability of highly purified and struc- 
turally characterized glycosphingolipid acceptors is 
one major factor determining the number and type 
of experiments that can be done in this area. 
Several methodological difficulties in the handling 
of amphipathic molecules may also be of in- 
fluence. As thin-layer chromatography has recent- 
ly [3-61 been shown to be a highly valuable tool in 
different binding assays (antibodies, lectins, tox- 
ins) it became natural to also test the thin-layer 
plate as a solid matrix for glycosphingolipid 
precursors in biosynthetic experiments. 
2. MATERIALS AND METHODS 
HPTLC plates, precoated with silica gel 60 
(Merck) on glass plates were used. After 
chromatographic development of the sample(s) in 
an appropriate solvent, the plate was dried and 
treated sequentially with polyisopropylmetha- 
crylated and 5% bovine serum albumin in phos- 
phate-buffered saline as in [6]. The thin-layer plate 
was then covered with incubation medium, ap- 
prox. 1 ml/10 cm2 (see below), and left at 37°C for 
3-4 h in saturated humid atmosphere. After in- 
cubation, the thin-layer plate was washed carefully 
6 times with phosphate-buffered saline and left to 
dry in the air. The dry plate was then subjected to 
autoradiography for 4-8 days using Kodak XAR-5 
X-ray film and a suitable developer. 
The first paper in this series appeared in Proc. of the 7th 
International Symposium on Glycoconjugates, Lund- 
Ronneby, July 17-23, 1983, pp. 425-426 
The incubation medium was composed essential- 
ly as in [7], and contained in a final volume of 1 
ml: 650~1 of enzyme preparation, about 1.3 x lo6 
cpm of GDP-L-[14C]fucose, 25 hl Tris-HCl buffer 
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(pH 7.5), 10,~mol NaNj, IOpmol ATP, 7.5 kmol 
MgC12, 0.1% Triton X-100. 
A microsomal preparation from pig intestinal 
mucosa was used as’ enzyme source and was 
prepared as follows: small intestine from pig was 
obtained fresh from the local slaughterhouse. The 
intestine was washed with saline to remove faeces 
and the mucosa was scrapped off with a spoon and 
stored at -70°C before use. Approx. 2 ml of 
mucosa was thawed and washed 3 times with 10 ml 
of phosphate-buffered saline (centrifugation 5 min 
in a laboratory bench centrifuge between each 
washing). The washed mucosa was then homogen- 
ized in 15 ml of ice-cold phosphate-buffered saline 
using a Dounce homogenizer (pestle B, 25 strokes) 
at 4°C. The homogenate was centrifuged at 450 x 
g for 10 min at 4°C. The pellet was discarded and 
the supernatant was further centrifugated at 4000 
x g for 5 min at 4°C. The pellet was again discard- 
ed and the supernatant was finally centrifuged at 
30 000 x g for 15 min at 4°C. The supernatant was 
discarded and the pellet resuspended in 15 ml of 
PBS and frozen to - 70°C before use. Protein con- 
centration varied between l-2.5 mg/ml for dif- 
ferent preparations. 
Total non-acid glycosphingolipid fractions from 
plasma of individual blood donors were prepared 
as in [8]. Lactotetraosylceramide was obtained 
from human meconium [9]. Gangliotetraosylcer- 
amide was obtained by acid treatment of GM1 
ganglioside from bovine brain. The major product 
was purified to homogeneity by DEAE-column 
chromatography and silicic acid chromatography. 
3. RESULTS 
Fig. 1 shows the result of a biosynthetic experi- 
ment in the solid phase on a thin-layer plate after 
chromatographic development of the glycosphin- 
golipid precursor fractions. Total non-acid glyco- 
sphingolipid fractions from plasma of 4 different 
blood donors (for blood group ABO, Lewis and 
secretor typing, see fig.1) were used as precursor 
mixtures, a microsomal preparation from pig small 
intestinal mucosa as enzyme source, and GDP- 
L-[‘4C]fucose as activated sugar. The anisalde- 
hyde-visualized section of the thin-layer plate 
shows the precursor fractions after chromato- 
graphic development and the figures to the left in- 
dicate the approximate number of carbohydrate 
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Fig. 1. Total non-acid glycosphingolipid fractions of 
plasma of 4 different blood donors (for blood group 
ABO, Lewis and secretor typing, see below photograph) 
were applied twice on a thin-layer plate: approx. 30 pg 
of each (Al,Bl,Cl and Dl) and approx. 10ag of each 
(A2,B2,C2 and D2). After chromatographic develop- 
ment in chloroform:methanol:water (60:35:8, by vol.) 
one section of the thin-layer plate (Al,Bl,Cl and Dl) 
was visualized with the anisaldehyde reagent [19]. The 
figures on the left hand side indicate the approximate 
number of sugars in the glycolipid carbohydrate chain. 
a, b, and c indicate tentatively the thin-layer position of 
the blood group H, type 1 chain pentaglycosylceramide, 
the blood group Lea pentaglycosylceramide and the 
blood group Leb hexaglycosylceramide [8,10-121, 
respectively. The remaining section (lanes A2,B2,C2 and 
D2) was incubated with an enzyme preparation from pig 
intestinal mucosa in the presence of GDP-L-[‘4C]-fucose 
for 3 h and subsequently subjected to autoradiography 
for 8 days (see section 2). 
units in the glycosphingolipid carbohydrate chain. 
The location of the blood group Leb hexaglycosyl- 
ceramide, the blood group Lea pentaglycosylcer- 
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Fig 2. The following glycosphingolipid precursors were applied on a thin-layer plate: Lactotetraosylceramide: Al, 2pg; 
A2, 0.2ag; A3, 0.02pg; A4, O.O02/rg. Gangliotetraosylceramide: Bl, 2pg; B2, 0.2gg; B3, 0.02pg; B4, 0.002pg. After 
chromatographic development in chloroform:methanol:water (60:35:8, by vol.) one section of the thin-layer plate (Al 
and Bl) was visualized by using the anisaldehyde reagent [19]. The remaining section Al-A4, Bl-B4 was incubated with 
an enzyme preparation from pig intestinal mucosa in the presence of GDP-L-[14C]fucose and subsequently subjected 
to autoradiography for 8 days. To visualize the precursor fractions after autoradiography, the thin-layer plate was ex- 
tracted several times with diethylether and finally treated with the anisaldehyde r agent. 
amide and the blood group H (type 1 carbohydrate 
chain) pentaglycosylceramide [8,1O-121 are also in- 
dicated. The autoradiogram, fig.1, shows the bio- 
synthesized, fucosylated, products with Rf values 
coinciding with their corresponding precursors. 
The bands seen on the autoradiogram are as clear 
and distinct as the ones shown after anisaldehyde 
visualization and both quantitative and qualitative 
differences are seen between the different in- 
dividual plasma fractions. No bands are seen on 
the autoradiogram over the cerebroside region (1 
sugar) or the globotriaosylceramide region (3 
sugars). Weaks bands are, however, seen over the 
lactosylceramide region (2 sugars) indicating fuco- 
sylation of this structure. 
Fig. 2 shows a similar experiment using dilution 
series of highly purified glycosphingolipid precur- 
sors, lactotetraosylceramide and gangliotetra- 
osylceramide. The autoradiogram shows that it is 
possible to detect a fucosylated product using as 
little as 2 ng of precursor. 
4. DISCUSSION 
One important aspect to consider when presen- 
ting a new non-conventional biosynthetic method 
is if the specificity of the enzymatic reaction is re- 
tained. Ideally a well characterized enzyme 
preparation of high purity and pure precursors 
should be used. This is not possible at the present 
stage. However, there is considerable indirect 
evidence to indicate that the specificity is retained. 
The enzyme preparation from pig intestinal 
mucosa is crude but the use of GDP-L-[14C]fucose 
restricts the study to fucosyltransferases. It is well 
known that porcine submaxillary gland contains 
large amounts of a ,&galactoside al-+2 fucosyl- 
transferase [131 and that porcine intestinal mucosa 
contain relatively large amounts of a blood group 
H pentaglycosylceramide with a type 1 chain ([14], 
unpublished). A Fuccv1-,2 transferase is thus ex- 
pected in the intestinal mucosa of pig. Using the 
experimental conditions described and some 15 
49 
Volume 167, number 1 FEBS LETTERS February 1984 
different highly purified well characterized glyco- radiogram in fig. 1 also shows very faint bands for 
sphingolipid precursors, the acceptor specificity of all 4 individuals over the lactosylceramide region. 
the enzyme preparation described, on a semiquan- This most probably indicates the biosynthesis of a 
titative basis, is very similar to that described [15] 112+-fucosyllactosylceramide. This structure has 
for the Fuccv1-,2 transferase of porcine submax- been described in rat intestinal epithelial cells [16] 
illary gland (to be published). and in mouse B cell hybridomas [17]. 
Fucosylation (Fuccu1’2) of both lactotetraosyl- 
ceramide and gangliotetraosylceramide is thus ex- 
pected [15] (fig. 2). The sensitivity, 2 ng, appears 
quite impressive but is of course dependent on the 
enzyme preparation. Using fresh saliva as the 
source of fucosyltransferase a similar detection 
level is about 0.1 pg (to be published). 
Fig. 1 illustrates the possibility of performing 
biosynthetic experiments using mixtures of accep- 
tor glycosphingolipids and yet on the thin-layer 
plate permitting separation and possibly identifica- 
tion of the precursors. This facility can be very 
useful in biosynthetic experiments in determining 
if the major component or a minor impurity in a 
precursor fraction is the true glycolipid acceptor. 
Furthermore, as in fig. 1, the total number of 
‘theoretical’ precursor glycosphingolipids from 
any organ or individual could be exposed for a 
given enzyme preparation in the presence of a 
suitable 14C-labelled sugar nucleotide. The results, 
although complex, are rather informative as the 
appearance of a band on the autoradiogram is in- 
terrelated to both the separation of possible 
precursors and the thin-layer mobility of the 
special precursor in question. If the structure of 
the precursor is known, the identification of the 
product is within reach. If the precursor is not 
known it may be profitable to try to isolate the pre- 
sumably new glycolipid formed. This experimental 
‘model may be advantageous as a screening pro- 
cedure when working with problems concerned 
with the understanding of how blood group- 
specific glycosphingolipid patterns come about 
and how genetic differences are expressed on the 
glycosphingolipid level. Fig. 1 thus tentatively 
shows that Fucxrl--+2 transferase acceptors are pre- 
sent in the plasma of all 4 individuals but differ 
both quantitatively and qualitatively possibly due 
to the interaction of Lewis and secretor genes and 
perhaps also due to other unknown genes. The 
presence of very complex thin-layer chromato- 
graphy (slow-moving) Fuccvl-+2 precursor 
glycosphingolipids in the Le(a-b-) non-secretor in- 
dividual has not been shown before. The auto- 
The strategy behind most glycosphingolipid ex- 
periments is to study the transfer of a radioactively 
labelled sugar nucleotide to a glycosphingolipid ac- 
ceptor [1,2]. To really ascertain that the biosyn- 
thesized product is a glycosphingolipid in conven- 
tional non-solid phase experiments a cumbersome 
and tedious extraction and preparation procedure 
is needed [ 181. Furthermore when using crude en- 
zyme preparations there is a risk of adding un- 
wanted exogenous precursor glycolipids. The 
described method minimizes this risk and abolishes 
the need for glycosphingolipid preparation after 
incubation. 
The advantages of the method combined with its 
relative swiftness and technical simplicity should 
make it at least complementary to other methods 
in the biosynthetic field. 
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